Daily practice and recent updates in the guidelines have made transcatheter aortic valve replacement (TAVR) a first-line treatment option for younger patients with lower surgical risk.1-4 As a result, it is estimated that the life expectancy of many TAVR patients will exceed the durability of their bioprosthetic valve; in many, a redo TAVR (ie, valve-in-valve in the failed transcatheter aortic valve [TAV]) may be indicated.
Ady Orbach
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ady
Contact Ady, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack